Phase II study of 5-FU dose-adjusted mFOLFOX7 plus Bevacizumab for patients with metastatic colorectal cancer(AJUST study)

ABSTRACT: Interventions: L-OHP 85mg/m^2 day1 Infusional 5-FU 2400mg/m^2 46hours l-LV 200mg/m^2 day1 Bmab 5mg/kg day1 every 2 weeks At first cycle, 5-FU concentrations are monitored. After second cycle, 5-FU are administered by the adjusted dose to mFOLFOX7+Bmab. Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622613 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR